Intake of Commercially Produced Fermented Soy Powder Q CAN PLUS® Favorably Changes Cholesterol and Isoflavone Intake in Individuals at High Risk of Cardiovascular Disease

Q CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN PLUS® on the nutrient composition of the habitual diets of individuals at high risk of cardiovascular diseases. We hypothesized that the nutrient profile...

Full description

Saved in:
Bibliographic Details
Published inCurrent developments in nutrition Vol. 4; no. Supplement_2; p. nzaa045_041
Main Authors Jung, Sarah, Sirirat, Rawiwan, Kim, Alice, Haddad, Ella, Sabaté, Joan
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Inc 01.06.2020
Oxford University Press
Subjects
Online AccessGet full text
ISSN2475-2991
2475-2991
DOI10.1093/cdn/nzaa045_041

Cover

Abstract Q CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN PLUS® on the nutrient composition of the habitual diets of individuals at high risk of cardiovascular diseases. We hypothesized that the nutrient profile, particularly nutrients associated with CVD risk, differs among individuals in the Q CAN PLUS® phase compared to the placebo phase. Study design was a randomized, controlled crossover intervention with twenty-four free living adults (29–75 years old; 80% female; 8% normal BMI, 45% overweight, 47% obese) at high risk of cardiovascular diseases. Subjects were randomized to receive either Q CAN PLUS® (fermented soy) powder or placebo powder for twelve weeks and switched over to the placebo treatment after two weeks of wash out period. Two 24-hour dietary recalls were collected during each phase which included one weekday and one weekend dietary recall. The nutrient consumption per day (mean ± SD) were based on a synthetic week by using the following formula: ((weekday * 5) +(weekday * 2))/7. On average, intake of cholesterol (211 ± 169 mg) was 13% lower (P = 0.05) in the Q CAN PLUS® phase compared to placebo (243 ± 179 mg). Total soy isoflavones (444 ± 210 mg) was 12 times higher (P < 0.0001) during Q CAN PLUS® phase than the placebo phase (33 ± 93 mg). Dietary total carbohydrate, total protein, vegetable protein, animal protein during Q CAN PLUS® phase were not statistically different from placebo phase. The differences in the intake of cholesterol and total soy isoflavones may have implications on risk of cardiovascular diseases. BESO Biological Research Inc Diamond Bar, CA, USA.
AbstractList ObjectivesQ CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN PLUS® on the nutrient composition of the habitual diets of individuals at high risk of cardiovascular diseases. We hypothesized that the nutrient profile, particularly nutrients associated with CVD risk, differs among individuals in the Q CAN PLUS® phase compared to the placebo phase.MethodsStudy design was a randomized, controlled crossover intervention with twenty-four free living adults (29–75 years old; 80% female; 8% normal BMI, 45% overweight, 47% obese) at high risk of cardiovascular diseases. Subjects were randomized to receive either Q CAN PLUS® (fermented soy) powder or placebo powder for twelve weeks and switched over to the placebo treatment after two weeks of wash out period. Two 24-hour dietary recalls were collected during each phase which included one weekday and one weekend dietary recall. The nutrient consumption per day (mean ± SD) were based on a synthetic week by using the following formula: ((weekday * 5) +(weekday * 2))/7.ResultsOn average, intake of cholesterol (211 ± 169 mg) was 13% lower (P = 0.05) in the Q CAN PLUS® phase compared to placebo (243 ± 179 mg). Total soy isoflavones (444 ± 210 mg) was 12 times higher (P < 0.0001) during Q CAN PLUS® phase than the placebo phase (33 ± 93 mg). Dietary total carbohydrate, total protein, vegetable protein, animal protein during Q CAN PLUS® phase were not statistically different from placebo phase.ConclusionsThe differences in the intake of cholesterol and total soy isoflavones may have implications on risk of cardiovascular diseases.Funding SourcesBESO Biological Research Inc Diamond Bar, CA, USA.
Q CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN PLUS® on the nutrient composition of the habitual diets of individuals at high risk of cardiovascular diseases. We hypothesized that the nutrient profile, particularly nutrients associated with CVD risk, differs among individuals in the Q CAN PLUS® phase compared to the placebo phase. Study design was a randomized, controlled crossover intervention with twenty-four free living adults (29–75 years old; 80% female; 8% normal BMI, 45% overweight, 47% obese) at high risk of cardiovascular diseases. Subjects were randomized to receive either Q CAN PLUS® (fermented soy) powder or placebo powder for twelve weeks and switched over to the placebo treatment after two weeks of wash out period. Two 24-hour dietary recalls were collected during each phase which included one weekday and one weekend dietary recall. The nutrient consumption per day (mean ± SD) were based on a synthetic week by using the following formula: ((weekday * 5) +(weekday * 2))/7. On average, intake of cholesterol (211 ± 169 mg) was 13% lower (P = 0.05) in the Q CAN PLUS® phase compared to placebo (243 ± 179 mg). Total soy isoflavones (444 ± 210 mg) was 12 times higher (P < 0.0001) during Q CAN PLUS® phase than the placebo phase (33 ± 93 mg). Dietary total carbohydrate, total protein, vegetable protein, animal protein during Q CAN PLUS® phase were not statistically different from placebo phase. The differences in the intake of cholesterol and total soy isoflavones may have implications on risk of cardiovascular diseases. BESO Biological Research Inc Diamond Bar, CA, USA.
ObjectivesQ CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN PLUS® on the nutrient composition of the habitual diets of individuals at high risk of cardiovascular diseases. We hypothesized that the nutrient profile, particularly nutrients associated with CVD risk, differs among individuals in the Q CAN PLUS® phase compared to the placebo phase.MethodsStudy design was a randomized, controlled crossover intervention with twenty-four free living adults (29–75 years old; 80% female; 8% normal BMI, 45% overweight, 47% obese) at high risk of cardiovascular diseases. Subjects were randomized to receive either Q CAN PLUS® (fermented soy) powder or placebo powder for twelve weeks and switched over to the placebo treatment after two weeks of wash out period. Two 24-hour dietary recalls were collected during each phase which included one weekday and one weekend dietary recall. The nutrient consumption per day (mean ± SD) were based on a synthetic week by using the following formula: ((weekday * 5) +(weekday * 2))/7.ResultsOn average, intake of cholesterol (211 ± 169 mg) was 13% lower (P = 0.05) in the Q CAN PLUS® phase compared to placebo (243 ± 179 mg). Total soy isoflavones (444 ± 210 mg) was 12 times higher (P < 0.0001) during Q CAN PLUS® phase than the placebo phase (33 ± 93 mg). Dietary total carbohydrate, total protein, vegetable protein, animal protein during Q CAN PLUS® phase were not statistically different from placebo phase.ConclusionsThe differences in the intake of cholesterol and total soy isoflavones may have implications on risk of cardiovascular diseases.Funding SourcesBESO Biological Research Inc Diamond Bar, CA, USA.
AbstractObjectivesQ CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN PLUS® on the nutrient composition of the habitual diets of individuals at high risk of cardiovascular diseases. We hypothesized that the nutrient profile, particularly nutrients associated with CVD risk, differs among individuals in the Q CAN PLUS® phase compared to the placebo phase. MethodsStudy design was a randomized, controlled crossover intervention with twenty-four free living adults (29–75 years old; 80% female; 8% normal BMI, 45% overweight, 47% obese) at high risk of cardiovascular diseases. Subjects were randomized to receive either Q CAN PLUS® (fermented soy) powder or placebo powder for twelve weeks and switched over to the placebo treatment after two weeks of wash out period. Two 24-hour dietary recalls were collected during each phase which included one weekday and one weekend dietary recall. The nutrient consumption per day (mean ± SD) were based on a synthetic week by using the following formula: ((weekday * 5) +(weekday * 2))/7. ResultsOn average, intake of cholesterol (211 ± 169 mg) was 13% lower ( P = 0.05) in the Q CAN PLUS® phase compared to placebo (243 ± 179 mg). Total soy isoflavones (444 ± 210 mg) was 12 times higher ( P < 0.0001) during Q CAN PLUS® phase than the placebo phase (33 ± 93 mg). Dietary total carbohydrate, total protein, vegetable protein, animal protein during Q CAN PLUS® phase were not statistically different from placebo phase. ConclusionsThe differences in the intake of cholesterol and total soy isoflavones may have implications on risk of cardiovascular diseases. Funding SourcesBESO Biological Research Inc Diamond Bar, CA, USA.
ArticleNumber nzaa045_041
Author Haddad, Ella
Jung, Sarah
Sabaté, Joan
Kim, Alice
Sirirat, Rawiwan
AuthorAffiliation 1 Loma Linda University, School of Public Health
3 Loma Linda University
2 Center for Nutrition and Healthy Lifestyles, Loma Linda University School of Public Health
AuthorAffiliation_xml – name: 2 Center for Nutrition and Healthy Lifestyles, Loma Linda University School of Public Health
– name: 3 Loma Linda University
– name: 1 Loma Linda University, School of Public Health
Author_xml – sequence: 1
  givenname: Sarah
  surname: Jung
  fullname: Jung, Sarah
  organization: Loma Linda University, School of Public Health
– sequence: 2
  givenname: Rawiwan
  surname: Sirirat
  fullname: Sirirat, Rawiwan
  organization: Center for Nutrition and Healthy Lifestyles, Loma Linda University School of Public Health
– sequence: 3
  givenname: Alice
  surname: Kim
  fullname: Kim, Alice
  organization: Loma Linda University, School of Public Health
– sequence: 4
  givenname: Ella
  surname: Haddad
  fullname: Haddad, Ella
  organization: Loma Linda University
– sequence: 5
  givenname: Joan
  surname: Sabaté
  fullname: Sabaté, Joan
  organization: Center for Nutrition and Healthy Lifestyles, Loma Linda University School of Public Health
BookMark eNqNUl1v0zAUjdCQGGPPvFriDanUduIkfpk0BcoqVTAok3izHPum9ZrYxU6Cyl9C4kfwy3BpNQ0kJp7ulX3OuR_nPk1OrLOQJM8JfkUwT6dK26n9JiXOmMAZeZSc0qxgE8o5ObmXP0nOQ7jFGBPOeY75afJ9bnu5AeQaVLmuA6-MbNsduvZODwo0moHvwPYxW7r47L5q8OgDqi7foevFzfLnDzSTo_OyjqRqLe0KQoyuhdCDdy2SVqN5cE0bURbQsZyxMdNmNHqQbUCyR1dmtUYfTdj8bkV6bdwogxpa6dFrE0AGeJY8biIazo_xLLmZvflUXU0W79_Oq8vFRKWMkklRFJBlADUjtC44xjqlpWRNzihVJWa4KRlQ1TQ5ZXXKi5TxBuuG1JgTmdU8PUsuDrrboe5Aqzi-l63YetNJvxNOGvHnjzVrsXKjKCgrCcVR4MVRwLsvQ9yEuHWDt7FnkZKcs4KXmEbU9IBS3oXgobmrQLDYuyqiq-Keq5Hx8sBww_Y_wPwAhriq0YAXQRmw0VPjQfVCO_MA9-IvrmqNNUq2G9hBuJuGiEAFFsv9ge3vi6a44DT_HAWKfws8WPoXcU7lfw
ContentType Journal Article
Copyright 2020 American Society for Nutrition.
American Society for Nutrition.
Copyright © The Author(s) on behalf of the American Society for Nutrition 2020. 2020
Copyright © The Author(s) on behalf of the American Society for Nutrition 2020.
Copyright_xml – notice: 2020 American Society for Nutrition.
– notice: American Society for Nutrition.
– notice: Copyright © The Author(s) on behalf of the American Society for Nutrition 2020. 2020
– notice: Copyright © The Author(s) on behalf of the American Society for Nutrition 2020.
DBID 6I.
AAFTH
AAYXX
CITATION
3V.
7RV
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
NAPCQ
PHGZM
PHGZT
PIMPY
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
5PM
DOI 10.1093/cdn/nzaa045_041
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
DatabaseTitleList Publicly Available Content Database




Database_xml – sequence: 1
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
DocumentTitleAlternate NUTRITION 2020 LIVE ONLINE Abstracts
EISSN 2475-2991
EndPage nzaa045_041
ExternalDocumentID PMC7258120
10_1093_cdn_nzaa045_041
10.1093/cdn/nzaa045_041
S247529912307926X
1_s2_0_S247529912307926X
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GroupedDBID .1-
.FO
0R~
7RV
7X7
8FI
8FJ
AAFWJ
AAHBH
AALRI
AAPXW
AAVAP
AAXUO
AAYWO
ABPTD
ABUWG
ABXVV
ACGFS
ACVFH
ADBBV
ADCNI
ADVLN
AEUPX
AFJKZ
AFKRA
AFPKN
AFPUW
AFRHN
AIGII
AITUG
AJUYK
AKBMS
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMNDL
AMRAJ
AOIJS
APXCP
BAYMD
BCNDV
BENPR
CCPQU
EBS
EJD
EMOBN
FDB
FYUFA
GROUPED_DOAJ
H13
HMCUK
HYE
IAO
IHR
INH
ITC
KSI
M~E
NAPCQ
O9-
OK1
PHGZM
PHGZT
PIMPY
PPXIY
PUEGO
RPM
UKHRP
Z5R
6I.
AAFTH
ABDBF
ABEJV
AFULF
BTTYL
ROX
TOX
AAYXX
CITATION
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
5PM
ID FETCH-LOGICAL-c3521-777e44eeb512b7900d328a5f6522c8050f85e2cff625b397359f0df1b091a4b93
IEDL.DBID 7X7
ISSN 2475-2991
IngestDate Thu Aug 21 13:56:58 EDT 2025
Fri Jul 25 09:20:55 EDT 2025
Wed Aug 06 19:27:10 EDT 2025
Tue Nov 19 12:02:23 EST 2024
Sat Aug 30 17:16:51 EDT 2025
Fri Aug 08 06:00:38 EDT 2025
Tue Aug 26 16:33:04 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Supplement_2
Language English
License http://creativecommons.org/licenses/by-nc-nd/4.0
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3521-777e44eeb512b7900d328a5f6522c8050f85e2cff625b397359f0df1b091a4b93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
OpenAccessLink https://www.proquest.com/docview/3169579802?pq-origsite=%requestingapplication%
PQID 3169579802
PQPubID 7121353
PageCount 1
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7258120
proquest_journals_3169579802
crossref_primary_10_1093_cdn_nzaa045_041
oup_primary_10_1093_cdn_nzaa045_041
elsevier_sciencedirect_doi_10_1093_cdn_nzaa045_041
elsevier_clinicalkeyesjournals_1_s2_0_S247529912307926X
elsevier_clinicalkey_doi_10_1093_cdn_nzaa045_041
PublicationCentury 2000
PublicationDate 20200601
PublicationDateYYYYMMDD 2020-06-01
PublicationDate_xml – month: 06
  year: 2020
  text: 20200601
  day: 01
PublicationDecade 2020
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
PublicationTitle Current developments in nutrition
PublicationYear 2020
Publisher Elsevier Inc
Oxford University Press
Publisher_xml – name: Elsevier Inc
– name: Oxford University Press
SSID ssj0001999609
Score 2.1078498
Snippet Q CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN PLUS® on the...
AbstractObjectivesQ CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of...
ObjectivesQ CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN...
SourceID pubmedcentral
proquest
crossref
oup
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage nzaa045_041
SubjectTerms Cardiovascular disease
Cholesterol
Dietary Bioactive Components
Gastroenterology and Hepatology
Proteins
Title Intake of Commercially Produced Fermented Soy Powder Q CAN PLUS® Favorably Changes Cholesterol and Isoflavone Intake in Individuals at High Risk of Cardiovascular Disease
URI https://www.clinicalkey.com/#!/content/1-s2.0-S247529912307926X
https://www.clinicalkey.es/playcontent/1-s2.0-S247529912307926X
https://dx.doi.org/10.1093/cdn/nzaa045_041
https://www.proquest.com/docview/3169579802
https://pubmed.ncbi.nlm.nih.gov/PMC7258120
Volume 4
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3dbtMwFLZgu-EGAQNRGJUlEOImquM4P75CZazaEFRlpVLvLDu2RbXijKWAxish8RA8GcdO0i0SG1eJkhzb0Tn2-Xz-jNALnjGTWaminEkSsaQkES8pj0yhJLNFBhrZ2zs-TLOjBXu3TJetwa1uwyq7NTEs1LoqvY18lMSZ9ygVhL4--xr5U6O8d7U9QuM22g2ly0Ce82V-aWPxaJ7wrqIPT0aldiP3U0oAMoKw-Dpl1Mt185CzHzB5RQNN7qG7LXTE44bX99Et4x6gvbGDbfOXC_wSh2DOYCXfQ7-O3UaeGlxZ7FNA_LFKcr2-wLNQ4NVoPIEV2Zfj1HhewePqhzbn-CM-GE_x7P1i_uc3nsjvIB4KiJoMhBquvvoTMKJaY-k0Pq4ru4avnMFtdysHd12GV43lBvs4Enyyqk_DUHrBr_ht4xx6iBaTw08HR1F7LkNUAlyLAZDnhjFjFIAFlXNCdEILmdoMsFxZkJTYIjW0tBb2VgrwTpJyS7SNFWATyRRPHqEdB2N7jLAhNtM2V5xoCcCNc0VJIkuTUmMtY2SAXnUMEmdN-Q3RuM0TAbwUV3g5QKRjoOiySmEdFKAarifJ_0Vi6nYe1yIWNRVEzCnLU1DcsQ-b5zRbDhDdUrZQpYEgN3f3HOTq__-x38md2I7jUvphzD1Z3Dbn64T337jV51AvPKcpwDjy5OaGn6I71NsSgoVpH-1szr-ZZwC4NmoYZtUQ7b45nM5OhsFs8RemnDLK
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5V7QEuCCiIQIGReIiLlfV6_TogFNpGCU2j0DRSbsuuvSuiBrvUgSr8JaT-CH4Zs36kjUTLqSdbtvdhzezMN7Mzs4S8jgOuAyOVE3JJHe4l1IkTFjs6UpKbKECNbP0dh8OgN-Gfpv50g1w0uTA2rLKRiaWgTvPE-sjbnhvYHaWIsg-n3x17apTdXW2O0KjY4kAvz9FkK97395C-bxjr7h_v9pz6VAEnQbDhIpwMNedaK1R1KowpTT0WSd8EiESSiPrURL5miTFoGSjU1p4fG5oaV6FmlVzZ4kso8re4zWjdJFsf94ejo0uvjrUfaNzUEIq9dpJm7eyXlAidBOXudepvLbvOgtz1EM0rOq97n9yrwSp0Ku56QDZ09pBsdzI01L8t4S2U4aOlX36b_O5nC3miITdgk07sQU5yPl_CqCwpq1Poog6wBUBTGOf4OD9P9Rl8ht3OEEaDyfjPBXTlT2RIhY2qnIcCr7beFJI-n4PMUugXuZnjV5mGerhZhndNTlkBcgE2cgWOZsVJOZW1cFvYq7ajHpHJrdDsMdnMcG5PCGhqgtSEKqaptDSMFaOeTLTPtDGc0xZ51xBInFYFP0S1Ue8JpKW4QssWoQ0BRZPHipJXoDK6vkn4rya6qCVHIVxRMEHFmPHQR6jg2kD9mAXTFmGrljU4qkDPzcO9Qr76_3_sNHwnVvO4XG845zVeXHVnK5Ovv8lmX8sK5SHzETjSpzd3_JLc6R0fDsSgPzx4Ru4y68ko_Vs7ZHNx9kM_R7i3UC_qNQbky20v67_dcmy2
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Intake+of+Commercially+Produced+Fermented+Soy+Powder+Q+CAN+PLUS%C2%AE+Favorably+Changes+Cholesterol+and+Isoflavone+Intake+in+Individuals+at+High+Risk+of+Cardiovascular+Disease&rft.jtitle=Current+developments+in+nutrition&rft.au=Jung%2C+Sarah&rft.au=Sirirat%2C+Rawiwan&rft.au=Kim%2C+Alice&rft.au=Haddad%2C+Ella&rft.date=2020-06-01&rft.pub=Oxford+University+Press&rft.eissn=2475-2991&rft.volume=4&rft.issue=Suppl+2&rft.spage=408&rft.epage=408&rft_id=info:doi/10.1093%2Fcdn%2Fnzaa045_041&rft.externalDocID=PMC7258120
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F24752991%2FS2475299120X04148%2Fcov150h.gif